PolackFP, ThomasSJ, KitchinN, et al.Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med, 2020; 383:2603–2615.
2.
AndersonEJ, RouphaelNG, WidgeAT, et al.Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med, 2020; 383:2427–2438.
3.
BadenLR, El SahlyHM, EssinkB, et al.Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med, 2021; 384:403–416.
4.
KarikóK, BucksteinM, NiH, et al.Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 2005; 23:165–175.
5.
PollardC, RejmanJ, De HaesW, et al.Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther, 2013; 21:251–259.
6.
SahinU, KarikóK, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov, 2014; 13:759–780.
7.
HouX, ZaksT, LangerR, et al.Lipid nanoparticles for mRNA delivery. Nat Rev Mater, 2021; 10:1–17.
8.
KimJ, EygerisY, GuptaM, et al.Self-assembled mRNA vaccines. Adv Drug Deliv Rev, 2021; 170:83–112.
9.
RosenblumHG, HadlerSC, MouliaD, et al.Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the Advisory Committee on Immunization Practices—United States, July 2021. MMWR Morb Mortal Wkly Rep, 2021; 70:1094–1099.
10.
PardiN, HoganMJ, PorterFW, et al.mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov, 2018; 17:261–279.
11.
BahlK, SennJJ, YuzhakovO, et al.Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther, 2017; 25:1316–1327.
12.
FeldmanRA, FuhrR, SmolenovI, et al.mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine, 2019; 37:3326–3334.
13.
SahinU, OehmP, DerhovanessianE, et al.An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature, 2020; 585:107–112.
14.
GillmoreJD, GaneE, TaubelJ, et al.CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med, 2021; 385:493–502.
15.
RheinbergerH-J. Jean Brachet (1909–1988). In eLS. John Wiley & Sons, Ltd., 2005. DOI:10.1002/9780470015902.a0025069
16.
GilbertW. Origin of life: the RNA world. Nature, 1986; 319:618–618.
17.
The Nobel Prize in Chemistry 2020. https://www.nobelprize.org/prizes/chemistry/2020/summary/ (last accessed September15, 2021).
18.
The Nobel Prize in Physiology or Medicine 2006. https://www.nobelprize.org/prizes/medicine/2006/summary/ (last accessed September15, 2021).
